At the news
? BEARISHIMPACT 7/10 425 filed Jun 24, 2026 at 16:16 ET
Passage Bio filed a definitive all-stock merger agreement to acquire Remix Therapeutics, where pre-merger Passage shareholders will own approximately 7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders receive contingent value rights tied to legacy gene therapy milestones.
- Passage Bio to merge with Remix Therapeutics via all-stock transaction; pre-merger Passage shareholders will own ~7% of combined company, Remix shareholders ~93%
- Remix equity value set at $226M, Passage equity value at $20M in the merger agreement
- Concurrent PIPE financing of at least $99,929,000 (Concurrent Investment Amount) led by Decheng Capital, with $69,999,999.28 from Subscription Agreement alone
- Combined company will be renamed Remix Therapeutics, Inc. and focus on advancing REM-422, an oral MYB mRNA degrader showing 43% ORR in adenoid cystic carcinoma
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access